MRK—As “failures” go, OS HR=0.80—[95% CI 0.64-0.98]—in KEYNOTE-604 is not such a bad result.
Meeting the PFS endpoint in KEYNOTE-604 (with HR=0.75) and being approved in third-line SCLC (#msg-149450826) ought to allow Keytruda to garner some meaningful business in SCLC, despite Tecentriq’s nominally better outcome in the first-line setting.
Right, I-133, HR was 0.70, p=0.007....so, to properly compare we need survival numbers. I do not think that those Keytruda results are bad, but there is room for improvement and Atezo is better.
Market Data 
Markets 
AI
